FUT11 Expression and Its Clinical Significance in Gastric Cancer

Abstract

Abstract Background: Gastric cancer (GC) is the most common and aggressively invasive malignancy within the digestive tract. Aberrant glycosylation proteins play a critical role in governing the malignancy of cancer cells and are associated with the advancement of multiple cancer forms. This current study aims to offer a more thorough and systematic comprehension of the expression and clinical relevance of FUT11 in GC, specifically focusing on its involvement in the initiation and progression of GC. Methods: We employ a range of publicly accessible databases, such as the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), to conduct an extensive investigation of FUT11 in the context of GC. Our analysis encompasses assessments of FUT11's expression levels, its influence on survival prognosis, and its clinical significance. In addition, we acquired GC tissue microarray sections from Suzhou Koch Biotech, comprising 75 individual patient cohorts, further to confirm the expression levels of FUT11 in GC tissues. Results: Data mining and analysis reveal elevated FUT11 expression in GC, independently associated with patient prognosis. Variable immune cell infiltration levels are observed in patients with differing FUT11 expression. FUT11's involvement in cancer pathways, particularly signal transduction, impacts GC onset and progression. Conclusions: This study reveals a notable rise in the expression of FUT11 in GC tissue. This increase is linked to a poor prognosis and may affect immune regulation. FUT11 may hold value as an immune and targeted therapeutic, presenting a fresh approach to treating GC.